Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma — a retrospective study

Safra, Tamar; Shamai, Sivan; Greenberg, Julia; Veizman, Anat; Shpigel, Shulem; Matcejevsky, D.; Pelles, Sharon; Inbar, Moshe; Levy, Tally; Grisaru, Dan

doi:10.1016/j.ygyno.2013.06.013

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no major bleeding events or peri‐operative mortality. The toxicity of the systemic chemotherapy is well known and has been previously described by us .…”

Section: Resultsmentioning

confidence: 95%

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

Safra

Grisaru

Inbar

et al. 2014

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…There were no major bleeding events or peri‐operative mortality. The toxicity of the systemic chemotherapy is well known and has been previously described by us .…”

Section: Resultsmentioning

confidence: 95%

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

Safra

Grisaru

Inbar

et al. 2014

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, this is particularly highlighted with adjuvant and palliative treatment of EOC whereby, carboplatin represents the preferential platinum agent due equivalent biological activity alongside its' superior toxicity profile. Although the myelosuppressive effects are well recognised, there is emerging evidence to confirming that this phenomenon can be circumvented when fractionated doses of carboplatin are combined with paclitaxel which induces platelet sparing effects [95]. Amongst most solid malignancies, the favourable non-haematological toxicity profile has undoubtedly promoted the use of carboplatin particularly in situations where cisplatin is contraindicated.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies

Woodward

Coward

2016

Critical Reviews in Oncology/Hematology

251

135

View full text Add to dashboard Cite

2 Highlights Platinum analogues, cisplatin and carboplatin, represent some of the most active cytotoxic agents in clinical oncology and are the backbone of most chemotherapeutic regimens  Despite relative similarities in mechanisms of action and activities, there are significant differences in both efficacy and toxicities for both platinum analogues in various malignancies  Carboplatin is a useful alternative in situations where cisplatin is contraindicated and this is not universally at the expense of efficacy  Platinum resistance, both de novo and acquired, is inevitable and understanding the mechanisms of resistance is essential in improving outcomes  Despite the burgeoning era of targeted therapies, the role of efficient DNA damaging agents such as platinum salts remains paramount especially in combination with these novel drugs.3 AbstractThe platinum analogues, cisplatin and carboplatin, are among the most widely used chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity in numerous malignancies including gynaecological cancers, germ cell tumours, head and neck cancer, thoracic cancers and bladder cancer. Although the final mechanism of inducing tumour cell apoptosis is similar for both compounds, cisplatin has been shown to be more effective in treating specific tumour types. Whilst more favourable toxicity profiles are often associated with carboplatin, this can frequently translate to inferior response in certain malignancies. This review succinctly collates the evidence for the preferential use of these platinum analogues in particular settings in addition to the long-standing dilemma surrounding the paucity of biomarkers predicting response to these agents.

show abstract

“…They also conducted a retrospective study in 2014 and compared the efficiency of these two methods as an adjuvant or neoadjuvant therapy. They reported that the use of a weekly regimen improved PFS, however, its overall survival was similar to that of three-week regimen (25). Alcarraz et al assessed the effect of neoadjuvant therapy using a dose-dense regimen.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the feasibility of using weekly paclitaxel as neoadjuvant therapy in patients with epithelial ovarian cancer; a pre-post clinical trial

et al. 2020

View full text Add to dashboard Cite

Introduction: Although weekly paclitaxel and carboplatin regimen is as effective as the standard method for treatment of advanced ovarian cancer, it has less frequently been used as neoadjuvant therapy. Objectives: To reduce the side effects of typical every three-week chemotherapy and increase progression-free survival (PFS) rate, this study aimed to evaluate the feasibility of using weekly paclitaxel as neoadjuvant therapy in patients with epithelial ovarian cancer. Patients and Methods: This pre-post clinical trial was conducted on 14 patients with stage IIIC (8 patients) and IV (6 patients) advanced ovarian carcinoma. All the patients received the three courses of treatment and then underwent interval debulking surgery. After the surgery, patients received three or five courses based on their stages. Every neoadjuvant chemotherapy course consisted of weekly paclitaxel (80 mg/m2 ) and carboplatin (AUC=6) every 3 weeks. After every 21 days of treatment course, the patients were evaluated to investigate their response to treatment and side effects. Patients were followed up for at least 6 months. Results: The mean (SD) age of the patients was 64±8 years. After three courses of neoadjuvant chemotherapy, one patient (7%) had a complete response and 13 patients (93%) had a partial response. During the treatment period, two patients (14%) developed anemia, one patient (7%) developed neutropenia, two patients (14%) developed thrombocytopenia, and six patients (43%) developed neuropathy. The median (interquartile range) of PFS was 13 months (9.5-16.25). Conclusion: The findings showed that a weekly paclitaxel and carboplatin regimen as neoadjuvant therapy could be effective in the treatment of advanced ovarian cancer. However, it is necessary to conduct multicenter studies with larger sample sizes. Trial registration: Registration of trial protocol has been approved in Iranian Registry of Clinical Trial (identifier: IRCT2017050333789N1; http://en.irct.ir/trial/25978)

show abstract

Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma — a retrospective study

Cited by 5 publications

References 25 publications

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies

Evaluation of the feasibility of using weekly paclitaxel as neoadjuvant therapy in patients with epithelial ovarian cancer; a pre-post clinical trial

Contact Info

Product

Resources

About